Cystic Fibrosis Neonatal Screen (Immunoreactive Trypsinogen)

Cystic Fibrosis Neonatal Screen (Immunoreactive Trypsinogen) is a newborn blood-spot screening test that measures immunoreactive trypsinogen, commonly abbreviated as IRT. The catalogue name uses the spelling “tripsinogen,” while the standard medical term is trypsinogen. IRT is a pancreatic enzyme precursor that may be increased in the blood of newborns with cystic fibrosis.

Cystic fibrosis is an inherited condition caused by disease-causing variants in the cystic fibrosis transmembrane conductance regulator gene, known as CFTR. CFTR protein dysfunction affects the movement of chloride and water across cell surfaces. This can produce thick secretions that affect the lungs, pancreas, digestive system, sinuses, reproductive tract and other organs.

In many newborns with cystic fibrosis, pancreatic ducts are obstructed or stressed, causing increased trypsinogen to enter the bloodstream. Measuring IRT from a dried blood spot helps identify babies with a greater probability of cystic fibrosis who need additional testing.

This is a screening test and not a diagnostic test. An increased IRT result does not mean that the baby definitely has cystic fibrosis. Prematurity, birth stress, illness and other temporary factors can also increase IRT. Conversely, a normal IRT result cannot exclude every case of cystic fibrosis.

Babies with an out-of-range screen may require a repeat IRT measurement, CFTR genetic testing or a diagnostic sweat chloride test, depending on the screening protocol. Parents should complete recommended follow-up promptly but should not assume that an abnormal screen is a confirmed diagnosis.

Benefits of Neonatal Cystic Fibrosis Screening

Symptoms of cystic fibrosis may not be obvious immediately after birth. Newborn screening aims to identify babies at increased risk before significant respiratory or nutritional complications develop. Early diagnostic confirmation allows specialist care to begin promptly when necessary.

• Measures immunoreactive trypsinogen from a small newborn dried blood spot.
• Identifies babies who may require further testing for cystic fibrosis.
• Supports earlier diagnosis before prominent symptoms develop.
• May allow earlier nutritional, pancreatic and respiratory assessment.
• Uses a minimally invasive heel-prick blood collection.
• Can be incorporated into a wider newborn metabolic screening programme.
• Helps direct appropriate CFTR genetic testing or sweat chloride testing.
• Supports timely referral to paediatric and cystic-fibrosis specialists.
• May reduce delays caused by waiting for recurrent respiratory or digestive symptoms.
• Provides useful screening information when interpreted with gestational age, collection timing and clinical findings.

Understanding Cystic Fibrosis

Cystic fibrosis follows an autosomal recessive inheritance pattern. A child usually develops the condition after inheriting one disease-causing CFTR variant from each biological parent. A person with only one disease-causing variant is generally described as a carrier and usually does not have classical cystic fibrosis.

CFTR dysfunction changes the salt and water balance of secretions. Thick mucus can obstruct airways and promote recurrent respiratory infections and inflammation. In the pancreas, obstruction can prevent digestive enzymes from reaching the intestine, causing difficulty absorbing fats, proteins and fat-soluble vitamins.

Possible early features include poor weight gain, frequent or bulky greasy stools, persistent cough, recurrent respiratory infections, salty-tasting skin and prolonged jaundice. Some babies are born with meconium ileus, a blockage of the intestine caused by unusually thick first stool.

Clinical severity varies widely. Some CFTR variants are associated with classical multisystem disease, while others may cause milder or organ-limited CFTR-related conditions. Newborn screening cannot predict the exact severity of future disease.

What Is Immunoreactive Trypsinogen?

Trypsinogen is an inactive precursor of the digestive enzyme trypsin and is produced by the pancreas. Small amounts may circulate in blood. In many newborns with cystic fibrosis, pancreatic obstruction or injury causes more trypsinogen to enter the bloodstream, resulting in an increased IRT measurement.

IRT concentration naturally changes during the first weeks of life and generally declines with age. The timing of specimen collection is therefore important. Laboratories use screening-programme-specific cut-offs based on the baby's age, collection protocol and analytical method.

IRT is sensitive enough to identify many babies who require further assessment, but it is not specific to cystic fibrosis. Most babies with an elevated initial IRT screen will not ultimately be diagnosed with cystic fibrosis. Follow-up testing is essential to distinguish affected babies from unaffected babies and carriers.

Newborn Screening Strategies

IRT-IRT Strategy: Some screening programmes measure IRT on the first dried blood spot and request a second specimen when the initial result exceeds the programme threshold. Persistently elevated IRT leads to diagnostic evaluation.

IRT-DNA Strategy: Other programmes perform CFTR variant analysis on the same blood spot when IRT is elevated. Identification of one or more selected CFTR variants influences the recommendation for sweat testing and specialist review.

IRT-DNA-Sequencing Strategy: Some programmes use a broader molecular step after an elevated IRT and initial DNA panel. This can improve detection but may identify variants with uncertain or variable clinical significance.

The test listed here should not be assumed to include CFTR genetic analysis unless this is explicitly stated by Focus Diagnostics. At the listed price, it may represent the IRT biochemical screen alone. Parents and clinicians should confirm the components and follow-up algorithm before collection.

Clinical Indications and Applications

Routine Newborn Screening: IRT testing may be included in a newborn screening panel for babies without symptoms. Screening is most useful when performed within the programme's recommended collection period.

Family History of Cystic Fibrosis: A baby with an affected sibling, known parental carrier status or another strong family history requires careful clinical and genetic evaluation. A normal IRT screen should not replace targeted CFTR testing or specialist advice in a high-risk family.

Meconium Ileus: Meconium ileus is strongly associated with cystic fibrosis. A baby with this condition needs urgent diagnostic assessment even if the IRT screen is normal, borderline or unavailable.

Suggestive Early Symptoms: Persistent respiratory symptoms, poor weight gain, malabsorption, bulky greasy stools, electrolyte disturbances or unusually salty sweat may justify diagnostic evaluation regardless of the newborn screen.

Abnormal Initial Screen: The test may be repeated as part of an IRT-IRT protocol. Follow the collection timing specified by the paediatrician or screening programme because cut-offs change with age.

Why Doctors Recommend This Test

Early diagnosis of cystic fibrosis allows affected infants to receive specialist nutritional and respiratory care during a critical period of growth. The care team can assess pancreatic function, monitor weight and growth, provide pancreatic enzyme replacement when indicated and develop respiratory management plans.

Newborn screening is particularly valuable because some babies initially appear healthy. Waiting until persistent symptoms develop may delay diagnostic evaluation. Screening narrows the group requiring confirmatory testing without subjecting every newborn to genetic or sweat testing.

The result must be handled carefully to avoid unnecessary alarm. An out-of-range screen indicates increased risk, not certainty. False-positive results are expected in screening programmes because the initial test is designed to identify as many potentially affected babies as reasonably possible.

Preparation Before the Test

No fasting is required. Feeding and prescribed medication can generally continue normally. The collection team should record the baby's date and time of birth, gestational age, birth weight, date and time of specimen collection and transfusion history.

Inform the laboratory if the baby was premature, critically ill, receiving intensive care or recently transfused. Prematurity, physiological stress and illness may influence IRT concentrations. Blood transfusion and other clinical factors may also affect parts of a broader newborn screening panel.

The ideal collection period depends on the newborn screening programme. Blood spots are commonly collected after the baby has reached the programme's minimum age and before hospital discharge. A specimen collected too early may require repetition.

Parents should not delay urgent clinical care while waiting for screening. A baby with breathing difficulty, intestinal obstruction, severe dehydration, poor feeding or other concerning symptoms requires immediate paediatric assessment.

Dried Blood Spot Collection Procedure

A trained healthcare professional warms and cleans the baby's heel and uses a sterile lancet to make a small puncture on the recommended outer or inner plantar surface. Gentle pressure allows drops of blood to form.

Each blood drop is applied directly to the marked circles on an approved newborn screening card. The blood must soak through the filter paper completely and fill each required circle. Layering repeated small drops, pressing the card against the heel or touching the collection area can produce an unsuitable specimen.

After collection, gentle pressure is applied to the heel until bleeding stops. The card is dried horizontally in a clean area away from direct sunlight, heat, moisture and chemical fumes. It is then transported according to newborn-screening requirements.

An insufficient, contaminated, compressed, layered, wet or improperly dried blood spot may require recollection. Prompt recollection is important because IRT changes as the baby grows older.

Laboratory Analysis and Reporting

The laboratory extracts blood components from the dried blood spot and measures IRT using a validated immunoassay. The result is compared with the screening programme's age-specific or percentile-based threshold.

The report may state screen negative, screen positive, within range, out of range or repeat specimen required. A numerical IRT concentration may also be provided. Screening thresholds are laboratory-specific and should not be compared directly with values from another programme.

If the screen is out of range, the next step depends on the protocol. It may involve another dried blood spot, CFTR variant analysis or direct referral for sweat chloride testing. Parents should follow the instructions given with the report.

Normal Reporting Time

The report for the Cystic Fibrosis Neonatal Screen (Immunoreactive Trypsinogen) is generally available within 2 to 3 working days after receipt of an acceptable dried blood spot. Recollection, repeat analysis, referral testing or an additional genetic stage may extend the turnaround time.

Who Should Consider This Test?

• Newborn babies undergoing routine metabolic and genetic disorder screening.
• Babies born into families with a history of cystic fibrosis.
• Newborns whose biological parents are known CFTR variant carriers.
• Babies requiring repeat IRT testing after an out-of-range initial result.
• Newborns specifically advised to undergo testing by a paediatrician or neonatologist.

Understanding the Screening Result

Screen Negative: A result within the programme threshold means the baby's risk is considered low based on the IRT screen. It does not guarantee that cystic fibrosis is absent. Further evaluation remains necessary when symptoms, meconium ileus or family history create strong clinical concern.

Screen Positive or Out of Range: An elevated IRT result indicates that the baby requires further assessment. Most babies with an elevated IRT result do not have cystic fibrosis. Repeat IRT, CFTR genetic analysis or a sweat chloride test may be recommended.

Elevated IRT with CFTR Variant: The meaning depends on the number and classification of variants detected. One variant may indicate carrier status or require further evaluation. Two disease-causing variants increase concern, but diagnostic confirmation and specialist interpretation remain necessary.

Unsatisfactory Specimen: An unsuitable blood spot cannot provide a reliable result. Recollection should be completed promptly according to laboratory instructions.

The sweat chloride test is the principal diagnostic test following a positive newborn screen. It measures chloride in sweat and should be performed at an experienced centre when the baby is old and large enough to provide an adequate specimen.

Clinical Limitations

IRT is a screening marker rather than a disease-specific marker. False-positive results can occur with prematurity, difficult delivery, neonatal stress and other illnesses. IRT cut-offs and follow-up protocols differ between screening programmes.

False-negative screens are possible. IRT may not be sufficiently elevated in every affected baby, particularly when collection timing or clinical circumstances alter the concentration. Babies with meconium ileus may require diagnostic evaluation regardless of the IRT result.

IRT testing cannot determine the exact CFTR genotype, predict disease severity or distinguish a carrier from an affected baby without further testing. If genetic analysis is performed, a limited panel may not detect rare CFTR variants.

A positive screen does not replace sweat chloride testing. A negative screen should not override persistent symptoms or a strong family history. Clinical judgement and follow-up are essential.

Important Safety Information

Parents should contact the paediatrician promptly after an out-of-range result and complete the recommended follow-up. They should not change feeding, begin pancreatic enzymes or use respiratory treatments without specialist advice.

Seek urgent medical care if a newborn has breathing difficulty, persistent vomiting, a swollen abdomen, failure to pass stool, marked sleepiness, poor feeding, signs of dehydration or reduced responsiveness. Screening results should never delay assessment of an unwell baby.